Sue Lee of World Courier provides a detailed analysis of
Southeast Asia, a growing pharmaceutical market with an
increase in clinical trials in recent years. Starting with a
depiction of the healthcare background, she then describes the
state of clinical trials in the region. With a population of about
620 million and a total area of 4.5 million square kilometres,
it contains the region’s well-recognised study destinations of
Malaysia, Singapore and Thailand, who are also members of
PIC/S, the Pharmaceutical Inspection Co-operation Scheme.
But what opportunities are there for multinational companies
to embark on activity outside of these established centres?